754 related articles for article (PubMed ID: 33521255)
1. Euglycemic Diabetic Ketoacidosis With COVID-19 Infection in Patients With Type 2 Diabetes Taking SGLT2 Inhibitors.
Vitale RJ; Valtis YK; McDonnell ME; Palermo NE; Fisher NDL
AACE Clin Case Rep; 2021; 7(1):10-13. PubMed ID: 33521255
[TBL] [Abstract][Full Text] [Related]
2. "Normal but Catastrophic" Euglycemic Diabetic Ketoacidosis Precipitated by Sodium-Glucose Cotransporter-2 Inhibitor Use: A Case Report.
Sarno MJF; Hernandez DPF; Matulac MO
Cureus; 2023 Nov; 15(11):e49236. PubMed ID: 38143642
[TBL] [Abstract][Full Text] [Related]
3. Euglycemic diabetic ketoacidosis in a patient with type 1 diabetes and SARS-CoV-2 pneumonia: case-report and review of the literature.
Oriot P; Hermans MP
Acta Clin Belg; 2022 Feb; 77(1):113-117. PubMed ID: 32544373
[TBL] [Abstract][Full Text] [Related]
4. Sodium-glucose cotransporter-2 inhibitor-associated euglycemic diabetic ketoacidosis in COVID-19-infected patients: A systematic review of case reports.
Khedr A; Hennawi HA; Khan MK; Eissa A; Mir M; Rauf I; Nitesh J; Surani S; Khan SA
World J Clin Cases; 2023 Aug; 11(24):5700-5709. PubMed ID: 37727728
[TBL] [Abstract][Full Text] [Related]
5. Euglycemic Diabetic Ketoacidosis Associated With Sodium-Glucose Cotransporter Type 2 Inhibitors in Patients With Type 2 Diabetes Mellitus Receiving Oral Therapy.
Dull RB; Spangler ML; Knezevich EL; Lau BM
J Pharm Pract; 2019 Apr; 32(2):240-243. PubMed ID: 29241389
[TBL] [Abstract][Full Text] [Related]
6. Euglycemic Diabetic Ketoacidosis Caused by SGLT2 Inhibitors and a Ketogenic Diet: A Case Series and Review of Literature.
Mistry S; Eschler DC
AACE Clin Case Rep; 2021; 7(1):17-19. PubMed ID: 33851013
[TBL] [Abstract][Full Text] [Related]
7. Hypertriglyceridemia-Induced Acute Pancreatitis, Euglycemic Diabetic Ketoacidosis and COVID-19 Infection in a Patient With Type 2 Diabetes Taking a Sodium-Glucose Cotransporter 2 Inhibitor.
Acevedo-Mendez BA; Ye Y; Hajizadeh N; Myers A
Cureus; 2021 Nov; 13(11):e19828. PubMed ID: 34853772
[TBL] [Abstract][Full Text] [Related]
8. Insulin and glucose infusion could prevent euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter 2 inhibitors.
Ito T; Sugasawa G; Suzuki F; Sunada M; Iwamuro K; Nakano T; Saito M; Maeba S
Indian J Thorac Cardiovasc Surg; 2022 Jan; 38(1):87-91. PubMed ID: 34898883
[TBL] [Abstract][Full Text] [Related]
9. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
Burke KR; Schumacher CA; Harpe SE
Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
[TBL] [Abstract][Full Text] [Related]
10. Severe euglycemic diabetic ketoacidosis secondary to sodium-glucose co-transporter 2 inhibitor: case report and literature review.
El Ess MS; ElRishi MA
Ann Med Surg (Lond); 2023 May; 85(5):2097-2101. PubMed ID: 37228937
[TBL] [Abstract][Full Text] [Related]
11. Fall, Fracture, and Two Episodes of Euglycemic Diabetic Ketoacidosis.
Wasey W; Hutchings S; Dufner A; Okon D; Saleh S
Cureus; 2022 Jun; 14(6):e25788. PubMed ID: 35812537
[TBL] [Abstract][Full Text] [Related]
12. Clinical and biochemical characteristics and analysis of risk factors for euglycaemic diabetic ketoacidosis in type 2 diabetic individuals treated with SGLT2 inhibitors: A review of 72 cases over a 4.5-year period.
Menghoum N; Oriot P; Hermans MP
Diabetes Metab Syndr; 2021; 15(6):102275. PubMed ID: 34562870
[TBL] [Abstract][Full Text] [Related]
13. The Significance of Precise Diabetes Diagnosis: A Case of Euglycemic Diabetic Ketoacidosis Induced by the Introduction of Empagliflozin with Simultaneous Reduction of Insulin Dosage.
Bińczyk W; Dróżdż O; Siudek B; Głuszczyk AM; Plizga JI; Grajnert FJ
Eur J Case Rep Intern Med; 2024; 11(6):004567. PubMed ID: 38846667
[TBL] [Abstract][Full Text] [Related]
14. Euglycemic diabetic ketoacidosis associated with sodium-glucose cotransporter-2 inhibitor use: a case report and review of the literature.
Diaz-Ramos A; Eilbert W; Marquez D
Int J Emerg Med; 2019 Sep; 12(1):27. PubMed ID: 31488052
[TBL] [Abstract][Full Text] [Related]
15. Euglycemic diabetic ketoacidosis associated with SGLT2i use: Case series.
Puls HA; Haas NL; Franklin BJ; Theyyunni N; Harvey CE
Am J Emerg Med; 2021 Jun; 44():11-13. PubMed ID: 33571749
[TBL] [Abstract][Full Text] [Related]
16. SGLT-2 inhibitors associated euglycemic and hyperglycemic DKA in a multicentric cohort.
Ata F; Yousaf Z; Khan AA; Razok A; Akram J; Ali EAH; Abdalhadi A; Ibrahim DA; Al Mohanadi DHSH; Danjuma MI
Sci Rep; 2021 May; 11(1):10293. PubMed ID: 33986421
[TBL] [Abstract][Full Text] [Related]
17. Euglycemic Diabetic Ketoacidosis Due to SGLT2 Inhibitor in a Patient With Gitelman Syndrome: A Therapeutic Dilemma.
Ahmed T; Karimi H; Hegde V; Lodhi SH
Cureus; 2021 Oct; 13(10):e19169. PubMed ID: 34873512
[TBL] [Abstract][Full Text] [Related]
18. Sodium-glucose cotransporter 2 inhibitor-induced euglycemic diabetic ketoacidosis in a patient with coronavirus disease 2019: a case report.
Yii ESS; Azli AW; Sitaram PN
J Med Case Rep; 2022 Jan; 16(1):17. PubMed ID: 34983625
[TBL] [Abstract][Full Text] [Related]
19. SGLT-2 inhibitors and euglycemic diabetic ketoacidosis/diabetic ketoacidosis in FAERS: a pharmacovigilance assessment.
He Z; Lam K; Zhao W; Yang S; Li Y; Mo J; Gao S; Liang D; Qiu K; Huang M; Wu J
Acta Diabetol; 2023 Mar; 60(3):401-411. PubMed ID: 36576563
[TBL] [Abstract][Full Text] [Related]
20. Unsuspected diabetic ketoacidosis after myocardial infarction in a patient treated with SGLT2 inhibitor increased length of stay in the hospital: how can it be prevented? A case report.
Oriot P; Hermans MP; Beauloye C; Rogghe PA; Noel S; Paternotte E
Eur Heart J Case Rep; 2023 Aug; 7(8):ytad336. PubMed ID: 37681058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
